ReviewCancers2022
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 40 citations in OpenAlex.
- Urinary calcium and bone resorption markers during 3 years of denosumab treatment in pediatric osteogenesis imperfecta.JBMR plus · 2025Trial
- Intralesional resection and autologous fibular graft reconstruction for a giant cell tumor of the fourth metacarpal with a secondary aneurysmal bone cyst: a case report.International journal of surgery case reports · 2026Article
- Giant Cell Tumor of the Distal Humerus: A Rare Location With a Good Response to Denosumab.Cureus · 2026Article
- Secondary Malignant Transformation of Giant Cell Tumor of Bone Nine Years After Initial Curettage: A Case Report and Literature Review.Reports (MDPI) · 2026Article
- Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence.Archives of orthopaedic and trauma surgery · 2026Article
- Giant Cell Tumor of Bone: Biology, Pathophysiology, and Histopathology in the Era of H3F3A.Biomedicines · 2026Review
- Combined Approach (Surgery + Systemic Adjuvant Therapy) in a Giant Cell Tumor of Proximal Femur: A Rare Case Report.Journal of orthopaedic case reports · 2026Article
- Intraoperative MRI for giant cell tumor of bone after denosumab and other selected tumors: A pilot study.Acta radiologica open · 2026Article
- Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis.South Asian journal of cancer · 2025Article
- Skip Lesion in Distal Femur with Recurrent Giant Cell Tumor of the Proximal Femur: A Very Rare Case Managed with Excision, Megaprosthesis Reconstruction, and Bone Cement Curettage.Journal of orthopaedic case reports · 2025Article
- Denosumab usage in atypical cemento-osseous dysplasia involving the entire mandible: a case report.BMC oral health · 2025Article
- Giant cell tumor of the bone with fatal pulmonary metastasis: A case report.SAGE open medical case reports · 2025Article
- Cellular crosstalk in the bone marrow niche.Journal of translational medicine · 2024Review
- A rare case of giant cell tumor of the anterior rib presenting as a breast mass.Radiology case reports · 2024Article
- Unusual Histopathological Challenges in Diagnosis of Giant Cell Tumor Cases Treated with Neoadjuvant Denosumab Chemotherapy: A Rare Case Report.Journal of orthopaedic case reports · 2024Article
- Comprehensive Insights into Chondroblastoma Metastasis: Metastatic Patterns and Therapeutic Approaches.Cancers · 2024Review
- Denosumab and metatarsal fracture healing: potential benefits with delayed remodeling: a case report.Annals of medicine and surgery (2012) · 2024Article
- Effect of denosumab in treatment of unresectable spine and sacrum giant cell tumor of bone.Musculoskeletal surgery · 2024Article
- Case report: A rare case of chondrosarcoma-like malignant giant cell tumor in adolescent rib: diagnostic challenges and treatment.Frontiers in oncology · 2024Article
- Repurposing of PSMA-targeted diagnostic and therapeutic agents for the detection and treatment of giant cell tumors of bone.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Despite the benign nature of the giant cell tumor of bone (GCTB), it shows a local recurrence rate of up to 50% and a chance of malignant transformation. The widely accepted local therapy in extremity GCTB is surgery, in the form of extended intralesional curettage with adequate disease clearance and retention of the limb, wherever possible. Denosumab, a human monoclonal antibody directed against the RANKL and associated inhibition of the RANKL pathway, is a relevant therapy option for advanced GCTB, to benefit tumor response and surgical down-staging. (2) The literature review of patients with GCTB treated with denosumab is performed via PubMed, using suitable keywords from January 2009 to January 2021. (3) Current indications for denosumab use are not definitively clear and unambiguous. Most GCTB patients with localized disease can be successfully treated with surgical curettage, and the role of denosumab in preoperative therapy in this patient population remains unclear. (4) However, patients with primary unresectable lesions or metastases may experience long-term clinical and radiological remission and pain control with denosumab treatment, and in this clinical situation, denosumab is currently the treatment of choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.